<DOC>
	<DOCNO>NCT00191971</DOCNO>
	<brief_summary>To investigate efficacy safety 2nd line GEM monotherapy CDDP regimen patient transitional cell carcinoma urothelium</brief_summary>
	<brief_title>2nd Line Gemcitabine Monotherapy Transitional Cell Carcinoma Urothelium ( TCC ) After CDDP Regimen</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urologic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologically and/or cytologically confirm TCC Received 1st line chemotherapy locally advance metastatic TCC CDDP regimen To least one measurable region PS : 02 To adequate organ function ( bone marrow , liver renal function ) To Interstitial pneumonia pulmonary fibrosis Within 4 week late chemotherapy radiotherapy To brain metastasis symptom To severe complication ( cardiac infarction , infection , drug hyper sensitivity diabetes )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Transitional cell carcinoma urothelium</keyword>
</DOC>